Eiger BioPharmaceuticals to Participate in Upcoming November 2021 Investor Conferences

Rhea-AI Summary

Eiger BioPharmaceuticals, a biopharmaceutical company focused on innovative therapies for Hepatitis Delta Virus (HDV) and rare diseases, will present corporate updates at two investor conferences in November 2021. David Cory, President and CEO, will speak at the Stifel 2021 Virtual Healthcare Conference on November 17 at 4:40 PM ET and at the Jefferies London Healthcare Conference on November 18 (pre-recorded). Both presentations will be webcasted, and Eiger will also conduct one-on-one investor meetings. The company has been granted FDA Breakthrough Therapy Designation for its HDV therapies.

PALO ALTO, Calif., Nov. 10, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases, today announced that David Cory, President and CEO, will provide a corporate update at two investor conference events in November:

• Stifel 2021 Virtual Healthcare Conference
• Wednesday, November 17 at 4:40 PM ET (live)

• Jefferies London Healthcare Conference
• Thursday, November 18 (pre-recorded)

Eiger will also host one-on-one meetings with investors at both conferences. 

Webcasts of the presentations will be available on the Eiger Biopharmaceuticals website at www.eigerbio.com in the Investors section. The Stifel presentation will be webcast live, and a replay will be available approximately one hour following the live event. The Jefferies presentation will be available at 3:00 AM ET on Thursday, November 18, 2021. 

About Eiger
Eiger is a commercial stage biopharmaceutical company focused on the development of therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy Designation.

For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Investors and Media:
Sri Ryali
Chief Financial Officer
Email: sryali@eigerbio.com
Phone: 1-650-272-6138 ext. 1007

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-upcoming-november-2021-investor-conferences-301420933.html

SOURCE Eiger BioPharmaceuticals, Inc.

FAQ

What conferences will Eiger BioPharmaceuticals participate in November 2021?

Eiger BioPharmaceuticals will participate in the Stifel 2021 Virtual Healthcare Conference on November 17 and the Jefferies London Healthcare Conference on November 18.

What time will Eiger's Stifel conference presentation be held?

The Stifel conference presentation will take place on November 17 at 4:40 PM ET.

Will Eiger BioPharmaceuticals' presentations be available to watch online?

Yes, Eiger's presentations will be webcasted and available on their website.

What is the focus of Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals focuses on developing therapies to treat and cure Hepatitis Delta Virus (HDV) and other rare diseases.

Have Eiger's therapies received any special designations?

Yes, all five rare disease programs by Eiger have been granted FDA Breakthrough Therapy Designation.